Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

112.52 -4.00 (-3.43%)

Streaming Delayed Price Updated: 2:07 PM EDT, Jun 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	127,496
Open	117.00
Bid (Size)	111.79 (300)
Ask (Size)	113.24 (100)
Prev. Close	116.51
Today's Range	109.59 - 117.00
52wk Range	20.20 - 151.18
Shares Outstanding	98,935,025
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

June 03, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 02, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+12.2%	+12.2%
1 Month	+7.1%	+7.1%
3 Month	-10.7%	-10.7%
6 Month	+26.4%	+26.4%
1 Year	+380.4%	+380.4%

More News

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

May 27, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

May 21, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗

May 07, 2026

Via Chartmill

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular

May 20, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

May 15, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

May 13, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

May 04, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

April 30, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 20, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

April 13, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

April 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

March 31, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

March 30, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

March 27, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗

March 25, 2026

Via The Motley Fool

Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗

March 24, 2026

Via The Motley Fool

Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

March 24, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

March 23, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

March 16, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

March 10, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

March 02, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?

Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?

Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?

The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market

What is the current price of Palvella Therapeutics, Inc. - Common Stock?

The current price of Palvella Therapeutics, Inc. - Common Stock is 112.52

When was Palvella Therapeutics, Inc. - Common Stock last traded?

The last trade of Palvella Therapeutics, Inc. - Common Stock was at 06/16/26 02:07 PM ET

What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?

The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 11.13B

How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?

Palvella Therapeutics, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.